Kesimpta's EU approval follows a green light in the US last August, and is based on the phase 3 ASCLEPIOS I and II studies, which showed Kesimpta was better than Sanofi’s Aubagio orally ...
It was approved on the strength of two phase 3 studies (ASCLEPIOS 1 and 2) which showed that Kesimpta was more effective than Sanofi’s Aubagio (teriflunomide) in reducing annualised relapse ...
Department of Neurology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China Objective: To study the cerebrospinal fluid (CSF) neurofilament light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback